Consensus Collegium Pharmaceutical, Inc.

Stocks

COLL

US19459J1043

Pharmaceuticals

Market Closed - Nasdaq Other stock markets 21:00:00 07/07/2026 BST			5-day change	1st Jan Change
36.44 ^USD	-2.75%		+0.66%	-21.30%

05-15	Collegium Pharmaceutical, Inc. Announces Appointment of Michael Donovan as Director	CI
05-12	Collegium completes acquisition of Azstarys® from Corium Therapeutics	RE

Evolution of the Average Target: Collegium Pharmaceutical, Inc.

Evolution of the Target Price: Collegium Pharmaceutical, Inc.

Changes in Analyst Recommendations: Collegium Pharmaceutical, Inc.

44b.Ar0TaV-5-S5_G5z-nozgGxmjspizgo8inrHD4dBbep4.RoxqHg_1tFQsU_mhqPmFenXxxP_Ksv5hzOCHm5ExDMtg91o_NuiAGC1K8w~e9462d64181fc846912c71509deb16e4

Analysts' recommendations: Collegium Pharmaceutical, Inc.

02-10	Truist Adjusts Price Target on Collegium Pharmaceutical to $58 From $55, Maintains Buy Rating	MT
01-07	Truist Securities Adjusts Price Target on Collegium Pharmaceutical to $55 From $48, Maintains Buy Rating	MT
12-09	Barclays Initiates Collegium Pharmaceutical at Overweight With $58 Price Target	MT
11-07	Truist Raises Price Target on Collegium Pharmaceutical to $48 From $45, Keeps Buy Rating	MT
08/08/25	Truist Raises Price Target on Collegium Pharmaceutical to $45 From $42, Keeps Buy Rating	MT
07/08/25	Collegium Pharma Q2 revenue beats analyst expectations	RE
10/01/25	Needham Upgrades Collegium Pharmaceutical to Buy From Hold, Price Target is $46	MT
09/08/24	Truist Securities Adjusts Price Target on Collegium Pharmaceutical to $42 From $40, Maintains Buy Rating	MT
30/07/24	HC Wainwright Upgrades Collegium Pharmaceutical to Buy From Neutral, Price Target is $47	MT
07/06/24	Jefferies Upgrades Collegium Pharmaceutical to Buy From Hold, Adjusts Price Target to $44 From $41	MT
10/05/24	Needham Downgrades Collegium Pharmaceutical to Hold From Buy	MT
10/05/24	Piper Downgrades Collegium Pharmaceutical to Neutral From Overweight, Price Target at $39	MT
26/02/24	Piper Sandler Adjusts Price Target on Collegium Pharmaceutical to $39 From $37, Maintains Overweight Rating	MT
26/02/24	Truist Adjusts Price Target on Collegium Pharmaceutical to $40 From $37, Maintains Buy Rating	MT
04/01/24	Truist Adjusts Collegium Pharmaceutical's Price Target to $37 From $31, Keeps Buy Rating	MT
04/01/24	Jefferies Downgrades Collegium Pharmaceutical to Hold From Buy, Raises Price Target to $37 From $30	MT
25/08/23	Needham Adjusts Price Target on Collegium Pharmaceutical to $36 From $35, Maintains Buy Rating	MT
02/05/23	Jefferies Assumes Collegium Pharmaceutical at Buy With $30 Price Target	MT
05/01/23	Needham Adjusts Price Target on Collegium Pharmaceutical to $35 From $34, Maintains Buy Rating	MT
04/11/22	Needham Adjusts Price Target on Collegium Pharmaceutical to $34 From $36, Maintains Buy Rating	MT
08/08/22	HC Wainwright Downgrades Collegium Pharmaceutical to Neutral From Buy	MT
06/04/22	Needham Adjusts Collegium Pharmaceutical's Price Target to $36 From $34, Keeps Buy Rating	MT
22/02/22	Piper Sandler Adjusts Collegium Pharmaceutical's Price Target to $42 From $36, Reiterates Overweight Rating	MT
15/02/22	Needham Adjusts Collegium Pharmaceutical's Price Target to $34 From $28, Reiterates Buy Rating	MT
15/02/22	HC Wainwright Adjusts Collegium Pharmaceutical's Price Target to $29 From $26, Reiterates Buy Rating	MT

More recommendations

Sector Comparison:

	Add to a list 0 selected To use this feature you must be a member Log in Sign up	Consensus	Analysts' recommendations evolution (4 months)	Financial estimates divergence	Analysts' Target price divergence	Objective/dr gap
	COLLEGIUM PHARMACEUTICAL, INC.					+49.1%
	ELI LILLY AND COMPANY					-0.59%
	JOHNSON & JOHNSON					-3.47%
	ABBVIE INC.					+1.44%
	ROCHE HOLDING AG					+5.81%
	NOVARTIS AG					-2.1%
	NOVO NORDISK A/S					-3.22%
	AMGEN INC.					-3.57%
	GILEAD SCIENCES, INC.					+16.14%
	PFIZER INC.					+20.49%
	Average					+8.00%
	Weighted average by Cap.					+0.93%